What BioEclipse Therapeutics does

BioEclipse Therapeutics is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics for patients with therapy-refractory solid tumors. Founded in 2006 as ConcentRx and rebranded in 2016, the company is headquartered in Mountain View, California, and operates from the Open Medicine Institute Collaboratory. Its pipeline centers on a proprietary platform that pairs cytokine-induced killer (CIK) cells with an oncolytic vaccinia virus, an architecture licensed exclusively from Stanford University and supported by preclinical data showing an approximately 1000-fold increase in cytotoxicity versus the individual components.

The lead asset, CRX100, is an autologous, intravenously administered combination currently in Phase 1b clinical trials for advanced solid tumors including ovarian, triple-negative breast, colorectal, hepatocellular carcinoma, osteosarcoma, and gastric cancers. A second asset, CRX200, is an allogeneic, off-the-shelf version of the platform positioned as IND-ready, intended to eliminate patient apheresis, reduce cell dose, and lower infusion burden. Clinical execution is concentrated at Moores Cancer Center (UC San Diego Health) and HonorHealth Research Institute (Scottsdale, AZ), with Stanford Women's Cancer Center's Oliver Dorigo serving as principal investigator on related work.

BioEclipse has no commercial products and is pre-revenue. Its economics will ultimately derive from pharmaceutical product sales following regulatory approval, supplemented by potential out-licensing or partnership transactions with larger pharmaceutical companies. To date it has raised approximately $9.3 million in equity through a June 2019 Series A-1 led by Revelis Capital Group and was awarded an approximately $8 million grant from the California Institute for Regenerative Medicine in April 2022. The company is led by CEO and co-founder Pamela Contag, Ph.D., whose prior company Xenogen was taken public, with a board that includes executives directly connected to the first FDA-approved cellular immunotherapy (Provenge/Dendreon).

Name

BioEclipse Therapeutics

Legal name

BioEclipse Therapeutics

Website

https://bioeclipse.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

BioEclipse Therapeutics is a clinical-stage biopharmaceutical company developing autologous (CRX100, Phase 1b) and allogeneic (CRX200, IND-ready) immuno-oncology therapies that combine cytokine-induced killer cells with an oncolytic virus to treat therapy-refractory solid tumors.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

Keywords

• Cancer immunotherapy
• Oncolytic virus therapy
• Solid tumor treatment
• Cell-based therapeutics
• Immuno-oncology platform

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. None currently - Pre-revenue clinical stage: BioEclipse Therapeutics is a clinical-stage biopharmaceutical company that is not yet generating revenue. The company is focused on developing its lead immunotherapy candidate CRX100 through Phase 1 clinical trials. Future revenue generation would come from pharmaceutical product sales following regulatory approval or from licensing/partnership agreements with larger pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

BioEclipse Therapeutics is a clinical-stage biopharmaceutical company that develops first-in-class, multi-mechanistic immuno-oncology therapeutics combining cytokine-induced killer (CIK) cells with an oncolytic virus to treat solid tumors. Its lead candidates are CRX100 (autologous, currently in Phase 1b clinical trials) and CRX200 (allogeneic, IND-ready), built on cell-therapy technology originally licensed from Stanford University.

Product overview

BioEclipse Therapeutics is a clinical-stage oncology company with a proprietary platform combining oncolytic virus technology with immune cell therapy. The company's portfolio consists of two immunotherapy products: CRX100 (autologous, Phase 1b), which combines cytokine-induced killer cells with an oncolytic virus and is being evaluated for treatment-resistant solid tumors; and CRX200 (allogeneic, IND ready), an off-the-shelf version offering superior manufacturing and administration advantages. Both products leverage a multi-mechanistic approach that activates innate immunity while generating adaptive immune responses against tumors.

Differentiator

Problem solved

Functional benefit

Products and services

• CRX100 Autologous multi-mechanistic immunotherapy candidate that combines cytokine-induced killer (CIK) cells with an oncolytic virus to treat solid tumors; currently in Phase 1b clinical trials. Targeted at oncology patients via clinical investigators at academic medical centers.
• CRX200 Next-generation allogeneic cell-based immunotherapy designed to remove the requirement for patient apheresis, enabling off-the-shelf treatment of solid tumors; currently IND-ready. Targeted at oncology patients and licensing partners.

Quantifiable outcome

• Phase 1 trial results showed stable disease in 1 patient with initial dose of 1E8 PFUs vaccinia plus 2-5E9 NK-T cells; 5 of 7 patients alive at 1-36 months post-treatment
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core.

• Stanford UniversitycoreTechnology or IntegrationTechnology exclusively licensed from Stanford University. CRX100 developed using patented Stanford technology. Clinical trial led by Principal Investigator Oliver Dorigo, MD, PhD from Stanford Women's Cancer Center.
• Moores Cancer Center at UC San Diego HealthcoreStrategic or Co-development PartnerFirst clinical trial site for Phase 1 dose-escalation trial of CRX100. Located in La Jolla, CA. Principal Investigator Sandip Patel, MD serves as Associate Professor at UC San Diego School of Medicine.
• HonorHealth Research InstitutecoreStrategic or Co-development PartnerClinical trial site in Scottsdale, Arizona for Phase 1 dose-escalation trial. Principal Investigator Jasgit Sachdev, MD is Director of Breast and Gynecological Early Phase Clinical Trials at HonorHealth.
• Spannerwerks, LLCcoreImplementation/ SI/ Consulting PartnerProfessional services firm assisting biopharma companies with development and launch of new products. Worked with BioEclipse to complete IND filing and prepare for Phase 1 clinical trial.
• Tiberend Strategic Advisors, Inc.coreStrategic or Co-development PartnerInvestor relations and media relations firm serving as contact for BioEclipse press inquiries. Provides communications support for corporate announcements.
• Mahmoud MahmoudiancoreOthersAppointed to BioEclipse Board of Directors in January 2022. Brings 30+ years of biopharma experience from Sumitomo Dainippon Pharma Oncology, Merck, and GlaxoSmithKline. Led $70M in capital to build academic and venture hubs at Sumitomo Oncology.
• Danforth AdvisorscoreImplementation/ SI/ Consulting PartnerManaging Director Stephen Ghiglieri serves as interim CFO for BioEclipse. Provides CFO services to life sciences companies.
• Johnson & Johnson Innovation - JLABScoreStrategic or Co-development PartnerBioEclipse was resident company at JLABS in South San Francisco from August 2017 to February 2020. Premier life science incubator program that provided expertise, connections, and team energy to help company grow to clinical-stage.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Targovax: Clinical-stage immuno-oncology company developing oncolytic virus (ONCOS-102) for solid tumors. Shares BioEclipse's oncolytic virus approach but is at earlier/mid clinical stage.

Direct peers

• Replimune: Clinical-stage oncology company developing a portfolio of oncolytic virus therapies (RP1, RP2, RP3) for solid tumors. Shares BioEclipse's oncolytic virus mechanistic approach but is at later clinical stage.
• Turnstone Biologics: Clinical-stage biotech developing oncolytic virus immunotherapies combined with cell therapy for solid tumors—directly analogous mechanism to BioEclipse's CRX100/CRX200 platform and the most head-to-head comparable peer.
• Celyad Oncology: Clinical-stage cell therapy company developing allogeneic CAR-T and NK cell therapies for solid tumors. Overlaps with BioEclipse on allogeneic cell therapy positioning for solid tumor indications.
• Adaptimmune Therapeutics: Cell therapy company developing engineered TCR-T therapies for solid tumors, with Tecelra FDA-approved for synovial sarcoma. Direct competitor in the cell therapy for solid tumors category.
• Iovance Biotherapeutics: Leader in tumor-infiltrating lymphocyte (TIL) cell therapy for solid tumors, including the FDA-approved Lifileucel. Competes directly with BioEclipse in autologous cell therapy for refractory solid tumors.
• Lokon Pharma: Clinical-stage gene therapy and oncolytic virus company developing combination approaches for solid tumors, including cell therapy + oncolytic virus strategies that overlap with BioEclipse's platform.
• Vyriad: Clinical-stage biotech developing oncolytic virus platforms (e.g., Voyager-V1) for solid tumor treatment. Directly comparable viral immunotherapy mechanism to BioEclipse's vaccinia virus component.

Broad incumbents

• Fate Therapeutics: Clinical-stage cell therapy company developing off-the-shelf, iPSC-derived NK and T-cell therapies for cancer. Comparable to BioEclipse's CRX200 allogeneic, off-the-shelf positioning with broader pipeline scale.
• Allogene Therapeutics: Leading allogeneic CAR-T developer with substantially greater capital and clinical pipeline. Comparable on allogeneic cell therapy platform positioning but focused primarily on hematologic malignancies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioEclipse Therapeutics